HbA1c, Coronary atheroma progression and cardiovascular outcomes.
Am J Prev Cardiol
; 9: 100317, 2022 Mar.
Article
en En
| MEDLINE
| ID: mdl-35112095
ACS, acute coronary syndrome; AQUARIUS, Aliskiren Quantative Atherosclerosis Regression Intravascular Ultrasound Study; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CVD, cardiovascular disease; Coronary atheroma progression; Diabetes mellitus; GLAGOV, Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound; HDL-C, high-density lipoprotein cholesterol; HbA1c; HbA1c, hemoglobin A1c; IBIS 2, The Integrated Biomarkers and Imaging Study-2; IVUS; IVUS, intravascular ultrasonography; LDL-C, lipoprotein cholesterol; MACE; MACE, major adverse cardiovascular events; NORMALISE, Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation; PAV, percent atheroma volume; PERISCOPE, Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation; PVD, peripheral vascular disease; REVERSAL, Reversal of Atherosclerosis With Aggressive Lipid Lowering; SATURN, The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin; STRADIVARIUS, Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabont The Intravascular Ultrasound Study; TG, triglycerides; UKPDS, UK Prospective Diabetes Study; hsCRP, high-sensitivity-CRP
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Año:
2022
Tipo del documento:
Article